The skin is the body’s largest organ and has many vital functions, such as protection from microbes and the elements. Skin diseases are common in all age groups and in all parts of the world. Some of the most common skin diseases are eczema, psoriasis, acne and skin cancer.
Atopic dermatitis (or atopic eczema) is a chronic, recurring inflammatory skin disease for which the incidence is rising. It is estimated that more than 20% of all children and 2–10% of the world adult population suffer from atopic dermatitis. Elidel is a patented drug for the treatment of atopic dermatitis based on the ingredient pimecrolimus. It is the first class of topical preparations for the treatment of atopic dermatitis which does not contain a corticosteroid and therefore has fewer side-effects. Elidel has been documented in studies involving more than 60,000 patients. Elidel is currently available for sale in 90 markets globally through Meda’s own marketing organization and via partners. In North America, Canada and Mexico, Elidel is out-licensed to Valeant. Elidel is recommended in the European guidelines as the first line treatment of atopic dermatitis in sensitive skin areas (e.g. the face). In 2012, a study in infants and children (2,400 patients treated for five years) with mild to moderate atopic dermatitis showed that Elidel has the same efficacy as topical steroids without any long-term safety concerns.
Actinic keratosis is an early stage to skin cancer that affects large areas of the skin and is a common type of cancer affecting an increasing percentage of the population, particularly in the northern hemisphere and in Australia. Zyclara is currently the only topical drug (used directly on the skin) that can detect and eliminate subclinical (invisible) and clinical (visible) lesions of actinic keratosis on large areas of the skin. The active ingredient in Zyclara is imiquimod (cream) 3.75%, a formulation that allows Zyclara to be used on a significantly larger treatment area than other preparations. Zyclara was approved in Europe in 2012 and the launch was initiated in 2013.
Aldara contains imiquimod 5%, an immunomodulating agent for the treatment of different forms of non-melanoma skin cancer such as small areas of actinic keratosis and superficial basal cell carcinoma (the most frequent skin tumor that rarely metastasizes), and external genital warts in men and women, an infection caused by the human papilloma virus (HPV) some subtypes of which are associated with
Acne is a chronic inflammatory disease that affects more than 80% of adolescents. Acnatac, indicated for the treatment of acne when inflammatory and non-inflammatory lesions are present, is in the launch phase. Clindamycin (antibacterial) and tretinoin (topical retinoid) in combination are more effective for the treatment of inflammatory and non-inflammatory acne than each of the ingredients individually, so-called monotherapy. Acnatac has a novel aqueous-based formula that provides a better safety profile than existing retinoid-based compounds and increases adherence. Acnatac has been tested clinically in more than 4,500 patients.
Betadine is an iodine-based antiseptic to treat and prevent infections of the skin and mucous membranes. It has a broad spectrum of antimicrobial activity that includes gram-positive and gram-negative bacteria, bacterial spores, fungi, protozoa and viruses. Betadine which has been on the market for more than 50 years, is marketed in seven European countries through Meda’s own organization. Under the Betadine brand there are six product lines addressing antiseptic needs in retail and hospital markets.
Other dermatology products
Meda has a well-diversified product portfolio, a global presence, and is represented within all areas of pharmaceuticals: Specialty Products, Cx, and OTC